MAIA Biotechnology Hits Key Milestone in NSCLC Trial with 90.5% Disease Control Rate
Event summary
- MAIA Biotechnology's Phase 3 THIO-104 trial for ateganosine in third-line NSCLC has enrolled 65 patients across 38 sites in 6 countries.
- Interim data from the Phase 2 THIO-101 trial showed a 90.5% disease control rate (DCR) for ateganosine sequenced with a checkpoint inhibitor in heavily pretreated NSCLC patients.
- The FDA granted Fast Track designation to ateganosine in July 2025, enabling potential accelerated approval and priority review.
- MAIA aims to randomize over 100 patients in the Phase 3 trial by year-end 2026.
The big picture
MAIA Biotechnology's progress in its Phase 3 trial for ateganosine highlights the potential of telomere-targeting therapies in addressing unmet needs in advanced NSCLC. The strong interim DCR data positions ateganosine as a promising candidate in a treatment landscape dominated by immunotherapy-resistant and chemotherapy-resistant patients. The FDA's Fast Track designation further accelerates the pathway to potential approval, underscoring the strategic importance of this novel mechanism in immuno-oncology.
What we're watching
- Regulatory Pathway
- Whether the Fast Track designation will expedite ateganosine's approval process and reduce time-to-market.
- Clinical Efficacy
- How the 90.5% DCR in Phase 2 translates into overall survival benefits in the Phase 3 trial.
- Market Entry
- The pace at which MAIA can capture the third-line NSCLC market, given the lack of current standard-of-care treatments.